drug · small molecule

ORILISSA

updated 2mo ago

by $ABBV AbbVie Inc.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval, with an approval for endometriosis.

targets

Gonadotropin-releasing hormone receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

ORILISSA

trade names

Elagolix sodium component of oriahnn, Orilissa

generic

ELAGOLIX SODIUM

MOA

12.1 Mechanism of Action ORILISSA is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.

indication

1 INDICATIONS AND USAGE ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis. Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ) [see D osage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 ) ] . ORILISSA is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis. ( 1 ) Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ). ( 1 )

ORILISSA

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside